KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gross Profit (2019 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Gross Profit for 7 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 184.09% year-over-year to $1.4 billion, compared with a TTM value of $3.0 billion through Dec 2025, up 56.4%, and an annual FY2025 reading of $3.0 billion, up 56.4% over the prior year.
  • Gross Profit was $1.4 billion for Q4 2025 at Alnylam Pharmaceuticals, up from $1.1 billion in the prior quarter.
  • Across five years, Gross Profit topped out at $1.4 billion in Q4 2025 and bottomed at -$40.2 million in Q1 2025.
  • Average Gross Profit over 5 years is $408.3 million, with a median of $283.4 million recorded in 2022.
  • The sharpest move saw Gross Profit skyrocketed 194.58% in 2023, then crashed 109.14% in 2025.
  • Year by year, Gross Profit stood at $224.9 million in 2021, then increased by 28.44% to $288.9 million in 2022, then increased by 27.31% to $367.7 million in 2023, then skyrocketed by 33.39% to $490.5 million in 2024, then soared by 184.09% to $1.4 billion in 2025.
  • Business Quant data shows Gross Profit for ALNY at $1.4 billion in Q4 2025, $1.1 billion in Q3 2025, and $631.7 million in Q2 2025.